Oscar Health has the most room to run among health insurers, which are rallying after the administration announced increased Medicaid budgets. CEO Mark Bertolini bought about $12 million of shares at the lows, the first insider purchase this year, and Oscar's market cap is just $3.74B. The chart confirms it: a broken daily descending trendline, surging money flow and a volume spike. Resistance sits at $14.15-$15, and a close above $15 brings the 200-day moving average into play. x.com 

Oscar Health's run has just started. The market liked the CEO buying stock, the reaffirmed 2026 guidance and last quarter's first-ever operating profit. x.com  x.com 

Oscar Health looks too extended after its big move and should pull back around earnings in the next few days; it is not a tech stock with a niche product capable of parabolic moves. x.com 

Oscar Health is set for a strong second half of 2026 and 2027 after management raised guidance by a massive amount and brought down its medical loss ratio, improving margins. On a $12 billion revenue guide, 2% margins at 25x earnings imply a $6 billion-plus market cap, and 5% margins in 2027 would mean $15 billion-plus, over 120% higher. An ACA subsidy extension looks unlikely but would be an unpriced tailwind. x.com 

Oscar Health's drop below $30 makes little sense after it crushed Q2, swung to a profit and raised full-year operating earnings guidance. Revenue was $4.90B versus $4.75B expected and EPS $1.10 versus $0.39, with FY26 revenue guided to $18.9B versus $18.6B estimated. The market needs time to digest the result, and the stock should recover soon; it remains a long-term hold. x.com  x.com  x.com 

Oscar Health is too hard to invest in given the state of the ACA, uncertainty over how much ICHRA can add and uncertain risk-adjustment liabilities. A full-year medical loss ratio below 80% would force rebates, though Oscar can still cut its expense ratio. Democrats winning at least partially in the midterms could bring more favorable terms for Oscar later. x.com 

Oscar Health could top $30 before the end of 2026 on margin expansion. It guides to $250-450M of operating earnings on $19B of 2026 revenue, 1.3-2.4% margins; insurers near 2.5% margins trade around 50% of revenue, implying about a $9.5B market cap at the high end versus $5.1B today. The long-term 5% margin target could support 1x revenue. CEO Mark Bertolini, one of the best CEOs now, buying 1M shares at $11.92 marked the bottom. x.com  x.com  x.com 

Oscar Health's ACA expansion offers a huge growth opportunity if it controls medical costs. It is entering six South Carolina counties in 2027; management targets another 400-600 counties by 2029. Q2 MLR fell to 79.2% from 91.1%, SG&A to 14.2% from 18.7%, and operating income rose from a $230M loss to a $389M profit. Favorable reserve development helped, so those results may not be the new normal. If underlying economics keep improving, Oscar could look very different in a few years. x.com  x.com 

Oscar Health's raised 2026 guidance changes nothing fundamentally, so its 18%+ premarket jump is unlikely to hold. Operating earnings guidance rose to $500-700M from $250-450M, but Oscar had already booked $704M in Q1 alone, more than the new top end, with Q3 and Q4 seasonally bringing losses. 2027 could be challenging as management targets a 5% margin, and the stock looks fairly valued around $34. x.com  x.com 

Oscar Health's new long-term targets could mean another 2.5x-4x over the next two years. It now targets 20% revenue CAGR by 2029, 5-7% operating margin and $4 EPS. If that translates into a 2.5%-5% net margin, healthcare names at those margins generally get 0.5x-1x sales. The market finds the targets credible since Oscar is well ahead of the 2027 guidance it gave three years ago, and Barclays raised its price target to $49 from $39 with a Buy rating. x.com